Breaking Down the Barriers to Hepatitis C Virus (HCV) Treatment Among Individuals With HCV/HIV Coinfection: Action Required at the System, Provider, and Patient Levels

The majority of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) coinfection occurs among persons who inject drugs. Rapid improvements in responses to HCV therapy have been observed, but liver-related morbidity rates remain high, given notoriously low uptake of HCV treatment. Advances...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 2013-03, Vol.207 (suppl_1), p.S19-S25
Main Authors: Grebely, Jason, Oser, Megan, Taylor, Lynn E., Dore, Gregory J.
Format: Article
Language:English
Subjects:
Antiviral Agents - therapeutic use
Coinfection - diagnosis
Coinfection - drug therapy
Coinfection - prevention & control
Hepatitis C - complications
Hepatitis C - diagnosis
Hepatitis C - drug therapy
Hepatitis C - prevention & control
Hepatitis C virus
Hepatitis C Virus-HIV Co-Infection
HIV Infections - complications
HIV Infections - diagnosis
HIV Infections - drug therapy
HIV Infections - prevention & control
Human immunodeficiency virus
Humans
Infection Control - methods
Substance Abuse, Intravenous - complications
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The majority of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) coinfection occurs among persons who inject drugs. Rapid improvements in responses to HCV therapy have been observed, but liver-related morbidity rates remain high, given notoriously low uptake of HCV treatment. Advances in HCV therapy will have a limited impact on the burden of HCV-related disease at the population-level unless barriers to HCV education, screening, evaluation, and treatment are addressed and treatment uptake increases. This review will outline barriers to HCV care in HCV/HIV coinfection, with a particular emphasis on persons who inject drugs, proposing strategies to enhance HCV treatment uptake and outcomes.
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/jis928